Loading...
Market
Story
Eli Lilly's Once-Weekly Insulin Shows Positive A1C Reductions in Phase 3 Trials
Sep 5, 2024, 10:57 AM
Eli Lilly announced positive topline data from its QWINT-1 and QWINT-3 Phase 3 clinical trials evaluating once-weekly insulin efsitora alfa in adults with type 2 diabetes. The trials demonstrated that the insulin led to non-inferior A1C reductions similar to daily insulin regimens, meeting their primary endpoints. This fixed dose study is the first of its kind, showcasing the potential of once-weekly insulin treatments for diabetes management.
View original story
Similar markets
0-10% • 25%
11-25% • 25%
26-50% • 25%
More than 50% • 25%
Below 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
Above 40% • 25%
Increase by less than 5% • 33%
Increase by 5% to 10% • 34%
Increase by more than 10% • 33%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Eli Lilly gains significant market share • 25%
Eli Lilly maintains current market share • 25%
Eli Lilly loses market share • 25%
No significant change • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Increase • 25%
Remain the same • 25%
Decrease • 25%
Other • 25%
Eli Lilly > 60% • 25%
Eli Lilly 40-60% • 25%
Novo Nordisk > 60% • 25%
Novo Nordisk 40-60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 33%
20% - 50% • 33%
More than 50% • 34%